EGFR/AURKB-IN-1

EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 occupies the hydrophobic region I or the αC-helix out pocket of EGFR and the back pocket of AURKB, inhibiting the growth, division and metastasis of tumor cells, thus can be used for cancer research[1].

Product Specifications

CAS Number

[3008543-34-5]

UNSPSC

12352005

Target

Aurora Kinase; EGFR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/egfr-aurkb-in-1.html

Purity

99.43

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CN1N=CC=C1C2=CC3=C(N=CN=C3N2)NC4=CC=C(C=C4)OCC5=CC=CC=C5

Molecular Formula

C23H20N6O

Molecular Weight

396.44

References & Citations

[1]Kurup S, et al. Design, synthesis, and evaluation of dual EGFR/AURKB inhibitors as anticancer agents for non-small cell lung cancer. Bioorg Med Chem Lett. 2024 Jan 8:129612.